What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Special Report: What Went Wrong With ACCORD?
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Recommended
Details
Presenters
Comments
Recommended
Overview
What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.
Facebook Comments